Trials / Completed
CompletedNCT01288963
IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma
The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 153 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.
Detailed description
Original tumor slides will be collected to identify tumor markers that may predict responses to treatment. Blood samples will be obtained prior to treatment with IL-2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IL-2 | Observation only |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2011-02-03
- Last updated
- 2023-06-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01288963. Inclusion in this directory is not an endorsement.